Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | QDPR | P09417 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073469 | 0.83 | HDAC1 (0.41) | HDAC1HDAC2HDAC3BACE1ESR2 | |
| SCHEMBL843886 | 0.79 | HDAC1 (0.44) | HDAC1HDAC2HDAC3BACE1ESR2 | |
| Cyanide SCHEMBL27811810 | 0.78 | HDAC1 (0.38) | HDAC1HDAC2HDAC3BACE1ESR2 | |
| SCHEMBL6940702 | 0.76 | HDAC2 (0.38) | HDAC1HDAC2HDAC3BACE1ESR2 | |
| SCHEMBL20870431 | 0.75 | HDAC1 (0.41) | HDAC1HDAC2HDAC3BACE1ESR2 | |
| SCHEMBL16956102 | 0.74 | ESR2 (0.33) | ESR2QDPRPOLBACMSDESR1 | |
| SCHEMBL1920801 | 0.74 | ESR2 (0.33) | ESR2QDPRKCNH2HRH3POLB | |
| SCHEMBL29326180 | 0.74 | QDPR (0.50) | HDAC2ESR2QDPRACMSDESR1 | |
| SCHEMBL2699251 | 0.74 | HDAC1 (0.37) | HDAC1HDAC2HDAC3BACE1ESR2 | |
| SCHEMBL3713659 | 0.74 | TDP1 (0.48) | HDAC1HDAC2HDAC3BACE1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151292-A | Indole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL | 2014-11-19 | — | — | CN | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2474530-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-102498097-A | Indole derivatives or pharmaceutically acceptable salts thereof | KISSEI PHARMACEUTICAL | 2012-06-13 | — | — | CN | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | HDAC1 566/4885HDAC2 507/4885HDAC3 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.